MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2024 International Congress

    Genetic signatures stratify PwP into three subgroups with differing responses in two disease-modifying Phase 3 trials and indicate multiple disease biology pathways to Parkinson’s Disease

    K. Hill, J. Cooper, J. Kozlowska, N. Olsen, R. Sultana, J. Surmeier, R. Wyse, N. Humphryes-Kirilov, A. Cooper (Sydney, Australia)

    Objective: To evaluate if 3 newfound genetic subgroups represent differing aspects of disease biology in PD by determining if subgroup participants have differing responses to…
  • 2024 International Congress

    A telehealth physical activity coaching program can maintain physical activity and exercise confidence in people with Parkison disease: a cohort study.

    D. Wani, A. Chandrana, A. Pacheco, D. Kipnis, J. Alomar, C. Macpherson, J. Fineman, L. Quinn (New York, USA)

    Objective: To examine the efficacy of the Engage-PD program in sustaining physical activity gains in people with Parkison disease. Background: Parkinson disease (PD) is a…
  • 2024 International Congress

    Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α-syn) as a potential gene therapy for Synucleinopathies

    S. Basu, V. Singh, N. Gattone, J. Li, B. Wicks, X. Huang, E. Fabyanic, S. Wang, M. Li, X. Qian, G. Rivera-Pena, C. Li, Z. Yu, P. Raman, E. Kostuk, MG. Biferi, E. Ramsburg (Philadelphia, USA)

    Objective: To develop an adeno-associated virus (AAV)-based artificial miRNA (miRNA) system targeting human α-syn. Background: Synucleinopathies such as Parkinson’s disease (PD) and Multiple System Atrophy…
  • 2024 International Congress

    Correlation between specific lower limb muscle strength and postural instability and gait difficulties in Parkinson’s disease

    M. van Emde-Boas, C. Pongmala, N. Bohnen (Ann Arbor, USA)

    Objective: To explore the relationship between the strength of specific lower limb musclegroups and their associations with PIGD motor features. Background: Postural instability and gait…
  • 2024 International Congress

    Investigating the genetic relationship between vitamin B12 deficiency and Parkinson’s disease

    K. Senkevich, R. Dering, M. Onvumere, L. Liu, P. Huot, Z. Gan-Or (Montreal, Canada)

    Objective: The aim of this study was to investigate the genetic association and causal link between vitamin B12 and the risk and progression of Parkinson's…
  • 2024 International Congress

    The 201 Trial in Untreated Parkinson’s Disease

    M. Werner, CW. Olanow, A. Mcgarry, C. Meyer, E. Mancino, C. Klint, J. Pellecchia (Atlanta, USA)

    Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…
  • 2024 International Congress

    the role of the “unfolded protein response” and the perk pathway in parkinson’s disease: study of genetic polymorphisms

    N. Palomba, E. Bianchini, D. Rinaldi, C. Strafella, V. Caputo, F. Garramone, P. Lombardo, F. Nicoletti, E. Giardina, T. Esposito, F. Pontieri, M. Alborghetti ()

    Objective: To study a possible association between polymorphisms of the genes coding for proteins involved in the UPR and the development of PD or PD…
  • 2024 International Congress

    GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation

    O. Siemeling, S. Slingerland, S. V/d Zee, T. van Laar (Groningen, Netherlands)

    Objective: To study the potential disease-modifying properties of ambroxol in PD patients with a GBA1 mutation Background: The most common genetic risk factor for Parkinson’s…
  • 2024 International Congress

    DPPX Autoimmune Encephalitis Associated with Severe Multifocal Dystonia.

    E. Roddy, E. Gentry, P. Hedera, V. Holiday, D. Robertson (LOUISVILLE, USA)

    Objective: To describe a novel motor phenomenology in an individual diagnosed with anti-DPPX encephalitis at our institution and to compare it with previously known phenotypic…
  • 2024 International Congress

    Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial

    E. Mitchell (London, United Kingdom)

    Objective: Slow-SPEED-UK is a randomized controlled trial investigating the effects of an app-based exercise program on individuals at higher risk of Parkinson’s Disease (PD). Background:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #25116 (not found)
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley